WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food and Drug Administration (“FDA”) for the treatme ...

The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.The double-blind, placebo-controlled trial will examine outcomes for hospitalized patients with severe babesiosis, a tick-borne illness often found as a co-infection of Lyme disease. WASHINGTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDA ...

60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -55%. A quarter ago, it was expected that this company would post a loss of $3.96 per share when it actually produced a loss of $4.23, delivering a surprise of -6.82%.Over the last four quarters, the compan ...

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in sales revenue and improvements in gross profit for Q3 2024, alongside increased operating expenses and a net loss attributable to common shareholders. Financial Highlights - Q3 2024 sales revenue increased 164% year-over-year to approximately $135 thousand from $51 thousand in Q3 2023 [3] - ARAKODA® pharmacy deliveries rose by 140% from 550 boxes in Q3 2023 to 1,319 boxes in Q3 2024 [3] - Gross profit improved to approximately $24 thousand in Q3 2024, compared to a gross loss of approximately $20 thousand in Q3 2023 [3] - Operating expenses were approximately $2.16 million in Q3 2024, up from approximately $1.58 million in Q3 2023 [3] - Net loss attributable to common shareholders was approximately $2.27 million, or ($0.93) per share, compared to a net income of approximately $4.09 million, or $9.13 per share in Q3 2023, representing a decline of $6.36 million [3] Business Highlights - The Company granted the University of Kentucky the right of reference to its NDA for ARAKODA®, facilitating FDA review of clinical efficacy and safety data [4] - A fixed-price contract was awarded to support commercial validation of new packaging for ARAKODA® by the United States Army Medical Materiel Development Activity [4] - Ethics approval was granted for an open label, expanded access study of ARAKODA® in immunosuppressed patients with persistent/relapsing babesiosis [4] - Clinical trial agreements were signed with all planned trial sites for the Tafenoquine Babesiosis Study [4] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and marketing new medicines for infectious diseases and achieved FDA approval for ARAKODA® in 2018 [5] - The Company collaborates with prominent research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private institutional investors [5]

Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile. WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; S ...

60 Degrees Pharmaceuticals (NASDAQ:SXTP) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria. This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied t ...

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to review 60 Degrees Pharma's regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company" or "60 Degrees Pharma" ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tickborne, potentially life-threatening illness Case studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunos ...